Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters










Publication year range
1.
Spinal Cord Ser Cases ; 6(1): 106, 2020 11 30.
Article in English | MEDLINE | ID: mdl-33257665

ABSTRACT

STUDY DESIGN: An analysis of reported cases. OBJECTIVES: To analyze the existing data on soccer (international football)-related spinal cord injury (SCI). SETTING: Cases of soccer (international football)-related SCI that were reported globally. METHODS: PubMed/MEDLINE, EMBASE, and online news publication databases were searched. RESULTS: Fourteen cases of football-related SCI that occurred between 1976 and 2020 were found. Average age at the time of injury was 19 and 86% of individuals were males. Eight of 14 individuals had vertebral fracture/dislocation, whereas two individuals had concomitant traumatic brain injury. Neurologically, 54% had tetraplegia, 39% had paraplegia, and 8% each suffered from hemiplegia and sensory deficit. Two cases could regain ability to walk with orthosis and four had full mobility with "Return to Play" (RTP). The mortality was 14%. CONCLUSIONS: Younger males were most commonly affected. The most common etiology, vertebral level of injury, and neurological manifestation was fall, cervical spine, and tetraplegia respectively. More than 50% of the individuals with football-related SCI were able to walk or RTP after rehabilitation. Further studies are required to establish universal RTP criteria and formulate preventive measures.


Subject(s)
Athletic Injuries , Soccer , Spinal Cord Injuries , Humans , Male , Cervical Vertebrae , Paraplegia/epidemiology , Paraplegia/etiology , Soccer/injuries , Spinal Cord Injuries/epidemiology , Spinal Cord Injuries/etiology , Athletic Injuries/epidemiology
3.
PM R ; 8(9S): S324-S325, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27673247
4.
Neurosci Biobehav Rev ; 65: 292-312, 2016 Jun.
Article in English | MEDLINE | ID: mdl-27048961

ABSTRACT

Neurodevelopmental disorders (NDDs) are highly prevalent and severely debilitating brain illnesses caused by aberrant brain growth and development. Resulting in cognitive, social, motor, language and affective disabilities, common NDDs include autism spectrum disorder (ASD), intellectual disability, communication/speech disorders, motor/tic disorders and attention deficit hyperactivity disorder. Affecting neurogenesis, glia/neuronal proliferation and migration, synapse formation and myelination, aberrant neural development occurs over a substantial period of time. Genetic, epigenetic, and environmental factors play a key role in NDD pathogenesis. Animal models are an indispensable tool to study NDDs. Paralleling clinical findings, we comprehensively evaluate various preclinical tests and models which target key (social, cognitive, motor) neurobehavioral domains of ASD and other common NDDs. Covering both traditional (rodent) and alternative NDD models, we outline the emerging areas of research and emphasize how preclinical models play a key role in gaining translational and mechanistic insights into NDDs and their therapy.


Subject(s)
Autistic Disorder , Neurodevelopmental Disorders , Animals , Autism Spectrum Disorder , Brain , Neurogenesis
5.
Brain Res Bull ; 125: 79-91, 2016 07.
Article in English | MEDLINE | ID: mdl-27113433

ABSTRACT

Neurodevelopmental disorders (NDDs) are a heterogeneous group of prevalent neuropsychiatric illnesses with various degrees of social, cognitive, motor, language and affective deficits. NDDs are caused by aberrant brain development due to genetic and environmental perturbations. Common NDDs include autism spectrum disorder (ASD), intellectual disability, communication/speech disorders, motor/tic disorders and attention deficit hyperactivity disorder. Genetic and epigenetic/environmental factors play a key role in these NDDs with significant societal impact. Given the lack of their efficient therapies, it is important to gain further translational insights into the pathobiology of NDDs. To address these challenges, the International Stress and Behavior Society (ISBS) has established the Strategic Task Force on NDDs. Summarizing the Panel's findings, here we discuss the neurobiological mechanisms of selected common NDDs and a wider NDD+ spectrum of associated neuropsychiatric disorders with developmental trajectories. We also outline the utility of existing preclinical (animal) models for building translational and cross-diagnostic bridges to improve our understanding of various NDDs.


Subject(s)
Environment , Genetic Therapy/methods , Neurodevelopmental Disorders/genetics , Neurodevelopmental Disorders/therapy , Translational Research, Biomedical , Advisory Committees/standards , Animals , Humans , Neurodevelopmental Disorders/psychology
6.
Aquat Toxicol ; 170: 297-309, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26372090

ABSTRACT

Zebrafish (Danio rerio) are rapidly emerging as an important model organism for aquatic neuropharmacology and toxicology research. The behavioral/phenotypic complexity of zebrafish allows for thorough dissection of complex human brain disorders and drug-evoked pathological states. As numerous zebrafish models become available with a wide spectrum of behavioral, genetic, and environmental methods to test novel drugs, here we discuss recent zebrafish phenomics methods to facilitate drug discovery, particularly in the field of biological psychiatry. Additionally, behavioral, neurological, and endocrine endpoints are becoming increasingly well-characterized in zebrafish, making them an inexpensive, robust and effective model for toxicology research and pharmacological screening. We also discuss zebrafish behavioral phenotypes, experimental considerations, pharmacological candidates and relevance of zebrafish neurophenomics to other 'omics' (e.g., genomic, proteomic) approaches. Finally, we critically evaluate the limitations of utilizing this model organism, and outline future strategies of research in the field of zebrafish phenomics.


Subject(s)
Neurons/metabolism , Proteomics , Zebrafish/physiology , Animals , Behavior, Animal/drug effects , Humans , Models, Animal , Neurons/drug effects , Psychotropic Drugs/toxicity , Toxicity Tests , Water Pollutants, Chemical/toxicity
7.
Expert Opin Drug Discov ; 11(1): 11-25, 2016.
Article in English | MEDLINE | ID: mdl-26558752

ABSTRACT

INTRODUCTION: Neurodevelopmental disorders (NDDs) are common and severely debilitating. Their chronic nature and reliance on both genetic and environmental factors makes studying NDDs and their treatment a challenging task. AREAS COVERED: Herein, the authors discuss the neurobiological mechanisms of NDDs, and present recommendations on their translational research and therapy, outlined by the International Stress and Behavior Society. Various drugs currently prescribed to treat NDDs also represent a highly diverse group. Acting on various neurotransmitter and physiological systems, these drugs often lack specificity of action, and are commonly used to treat multiple other psychiatric conditions. There has also been relatively little progress in the development of novel medications to treat NDDs. Based on clinical, preclinical and translational models of NDDs, our recommendations cover a wide range of methodological approaches and conceptual strategies. EXPERT OPINION: To improve pharmacotherapy and drug discovery for NDDs, we need a stronger emphasis on targeting multiple endophenotypes, a better dissection of genetic/epigenetic factors or "hidden heritability," and a careful consideration of potential developmental/trophic roles of brain neurotransmitters. The validity of animal NDD models can be improved through discovery of novel (behavioral, physiological and neuroimaging) biomarkers, applying proper environmental enrichment, widening the spectrum of model organisms, targeting developmental trajectories of NDD-related behaviors and comorbid conditions beyond traditional NDDs. While these recommendations cannot be addressed all in once, our increased understanding of NDD pathobiology may trigger innovative cross-disciplinary research expanding beyond traditional methods and concepts.


Subject(s)
Drug Design , Drug Discovery/methods , Neurodevelopmental Disorders/drug therapy , Animals , Biomarkers/metabolism , Disease Models, Animal , Endophenotypes/metabolism , Humans , Neurodevelopmental Disorders/genetics , Neurodevelopmental Disorders/physiopathology , Neurotransmitter Agents/metabolism , Translational Research, Biomedical/methods
8.
Zebrafish ; 12(5): 339-48, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26244595

ABSTRACT

Zebrafish are emerging as an important model organism for neurobehavioral phenomics research. Given the likely variation of zebrafish behavioral phenotypes between and within laboratories, in this study, we examine the influence and variability of several common environmental modifiers on adult zebrafish anxiety and locomotor activity. Utilizing the novel tank paradigm, this study assessed the role of various laboratory factors, including experimenter/handling, testing time and days, batch, and the order of testing, on the behavior of a large population of experimentally naive control fish. Although time of the day, experimenter identity, and order of testing had little effect on zebrafish anxiety and locomotor activity levels, subtle differences were found for testing days and batches. Our study establishes how zebrafish behaviors are modulated by common environmental/laboratory factors and outlines several implications for zebrafish neurobehavioral phenomics research.


Subject(s)
Anxiety , Environment , Models, Animal , Motor Activity , Zebrafish/physiology , Animals , Female , Male , Phenotype
9.
Expert Opin Investig Drugs ; 24(4): 543-56, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25727478

ABSTRACT

INTRODUCTION: Anxiety spectrum disorders (ASDs) are highly prevalent psychiatric illnesses that affect millions of people worldwide. Strongly associated with stress, common ASDs include generalized anxiety disorder, panic, social anxiety, phobias and drug-abuse-related anxiety. In addition to ASDs, several other prevalent psychiatric illnesses represent trauma/stressor-related disorders, such as post-traumatic stress disorder and acute stress disorder. Anxiolytic drugs, commonly prescribed to treat ASDs and trauma/stressor-related disorders, form a highly heterogenous group, modulating multiple neurotransmitters and physiological mechanisms. However, overt individual differences in efficacy and the potential for serious side-effects (including addiction and drug interaction) indicate a need for further drug development. Yet, over the past 50 years, there has been relatively little progress in the development of novel anxiolytic medications, especially when promising candidate drugs often fail in early clinical trials. AREAS COVERED: Herein, the authors present recommendations of the Task Force on Anxiolytic Drugs of the International Stress and Behavior Society on how to improve anxiolytic drug discovery. These recommendations cover a wide spectrum of aspects, ranging from methodological improvements to conceptual insights and innovation. EXPERT OPINION: In order to improve the success of anxiolytic drugs in early clinical trials, the goals of preclinical trials may need to be adjusted from a clinical perspective and better synchronized with those of clinical studies. Indeed, it is important to realize that the strategic goals and approaches must be similar if we want to have a smoother transition between phases.


Subject(s)
Anti-Anxiety Agents/therapeutic use , Drug Design , Animals , Anti-Anxiety Agents/adverse effects , Anxiety Disorders/drug therapy , Anxiety Disorders/physiopathology , Clinical Trials as Topic/methods , Drug Evaluation, Preclinical/methods , Humans
10.
Neurochem Int ; 66: 15-26, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24412511

ABSTRACT

Autism spectrum disorder (ASD) is a debilitating brain illness causing social deficits, delayed development and repetitive behaviors. ASD is a heritable neurodevelopmental disorder with poorly understood and complex etiology. The central dopaminergic system is strongly implicated in ASD pathogenesis. Genes encoding various elements of this system (including dopamine receptors, the dopamine transporter or enzymes of synthesis and catabolism) have been linked to ASD. Here, we comprehensively evaluate known molecular interactors of dopaminergic genes, and identify their potential molecular partners within up/down-steam signaling pathways associated with dopamine. These in silico analyses allowed us to construct a map of molecular pathways, regulated by dopamine and involved in ASD. Clustering these pathways reveals groups of genes associated with dopamine metabolism, encoding proteins that control dopamine neurotransmission, cytoskeletal processes, synaptic release, Ca(2+) signaling, as well as the adenosine, glutamatergic and gamma-aminobutyric systems. Overall, our analyses emphasize the important role of the dopaminergic system in ASD, and implicate several cellular signaling processes in its pathogenesis.


Subject(s)
Child Development Disorders, Pervasive/genetics , Dopamine Plasma Membrane Transport Proteins/genetics , Dopamine/genetics , Dopaminergic Neurons/physiology , Receptors, Dopamine/genetics , Signal Transduction/physiology , Animals , Brain/physiology , Child Development Disorders, Pervasive/diagnosis , Child Development Disorders, Pervasive/metabolism , Dopamine/metabolism , Dopamine Plasma Membrane Transport Proteins/metabolism , Humans , Neural Pathways/physiology , Receptors, Dopamine/metabolism
11.
Article in English | MEDLINE | ID: mdl-24315837

ABSTRACT

Autism spectrum disorder (ASD) is a serious neurodevelopmental disorder with complex symptoms and unclear, multi-factorial pathogenesis. Animal (rodent) models of ASD-like behavior are extensively used to study genetics, circuitry and molecular mechanisms of ASD. The evolutionarily conserved nature of social behavior and its molecular pathways suggests that alternative experimental models can be developed to complement and enhance the existing rodent ASD paradigms. The zebrafish (Danio rerio) is rapidly becoming a popular model organism in neuroscience and biological psychiatry to study brain function, model human brain disorders and explore their genetic or pharmacological modulation. Representing highly social animals, zebrafish emerge as a strong potential model organism to study normal and pathological social phenotypes, as well as several other ASD-like symptoms. Here, we discuss the developing utility of zebrafish in modeling ASD as a new emerging field in translational neuroscience and drug discovery.


Subject(s)
Child Development Disorders, Pervasive , Disease Models, Animal , Zebrafish , Animals , Brain/physiology , Child Development Disorders, Pervasive/chemically induced , Child Development Disorders, Pervasive/genetics , Child Development Disorders, Pervasive/physiopathology , Child Development Disorders, Pervasive/psychology , Humans , Social Behavior
12.
Brain Res Bull ; 98: 145-54, 2013 Sep.
Article in English | MEDLINE | ID: mdl-24007957

ABSTRACT

Skin coloration can be affected by many genetic, environmental and pharmacological factors. Zebrafish (Danio rerio) are a useful and versatile model organism in biomedical research due to their genetic tractability, physiological homology to mammals, low cost, reproducibility and high throughput. Zebrafish coloration is mediated by chromatophores - the skin color pigment cells largely controlled by endocrine and neural mechanisms. The characteristic darkening of zebrafish skin is caused by the dispersion (and paling - by aggregation) of melanosomes (pigment-containing organelles), which show high homology to mammalian structures. Various pharmacological agents potently affect zebrafish coloration - the phenotype that often accompanies behavioral effects of the drugs, and may be used for drug discovery. Although zebrafish behavior and skin responses are usually not directly related, they share common regulatory (neural, endocrine) mechanisms, and therefore may be assessed in parallel during psychotropic drug screening. For example, some psychoactive drugs can potently affect zebrafish skin coloration. Can we use this knowledge to refine phenotype-driven psychotropic drug discovery? Here, we present current models using zebrafish skin coloration assays, and discuss how these models may be applied to enhance in vivo CNS drug discovery.


Subject(s)
Central Nervous System Agents/pharmacology , Drug Discovery , Models, Animal , Skin Pigmentation/drug effects , Zebrafish/anatomy & histology , Animals , Skin Pigmentation/genetics , Zebrafish/genetics
13.
Behav Brain Res ; 256: 172-87, 2013 Nov 01.
Article in English | MEDLINE | ID: mdl-23948218

ABSTRACT

Recently, the pathophysiological overlap between metabolic and mental disorders has received increased recognition. Zebrafish (Danio rerio) are rapidly becoming a popular model organism for translational biomedical research due to their genetic tractability, low cost, quick reproductive cycle, and ease of behavioral, pharmacological or genetic manipulation. High homology to mammalian physiology and the availability of well-developed assays also make the zebrafish an attractive organism for studying human disorders. Zebrafish neurobehavioral and endocrine phenotypes show promise for the use of zebrafish in studies of stress, obesity and related behavioral and metabolic disorders. Here, we discuss the parallels between zebrafish and other model species in stress and obesity physiology, as well as outline the available zebrafish models of weight gain, metabolic deficits, feeding, stress, anxiety and related behavioral disorders. Overall, zebrafish demonstrate a strong potential for modeling human behavioral and metabolic disorders, and their comorbidity.


Subject(s)
Disease Models, Animal , Mental Disorders/physiopathology , Metabolic Diseases/physiopathology , Zebrafish/physiology , Animals , Humans , Obesity/physiopathology , Stress, Psychological/physiopathology
14.
ACS Chem Neurosci ; 4(8): 1137-50, 2013 Aug 21.
Article in English | MEDLINE | ID: mdl-23883191

ABSTRACT

Among different classes of psychotropic drugs, hallucinogenic agents exert one of the most prominent effects on human and animal behaviors, markedly altering sensory, motor, affective, and cognitive responses. The growing clinical and preclinical interest in psychedelic, dissociative, and deliriant hallucinogens necessitates novel translational, sensitive, and high-throughput in vivo models and screens. Primate and rodent models have been traditionally used to study cellular mechanisms and neural circuits of hallucinogenic drugs' action. The utility of zebrafish ( Danio rerio ) in neuroscience research is rapidly growing due to their high physiological and genetic homology to humans, ease of genetic manipulation, robust behaviors, and cost effectiveness. Possessing a fully characterized genome, both adult and larval zebrafish are currently widely used for in vivo screening of various psychotropic compounds, including hallucinogens and related drugs. Recognizing the growing importance of hallucinogens in biological psychiatry, here we discuss hallucinogenic-induced phenotypes in zebrafish and evaluate their potential as efficient preclinical models of drug-induced states in humans.


Subject(s)
Behavior, Animal/drug effects , Disease Models, Animal , Hallucinogens/pharmacology , Psychotropic Drugs/pharmacology , Zebrafish/physiology , Animals , Anxiety/physiopathology , Behavior, Animal/physiology , Biomarkers/metabolism , Biomedical Research/methods , Cognition/drug effects , Cognition/physiology , Drug Evaluation, Preclinical , Motor Activity/drug effects , Motor Activity/physiology , Phenotype , Psychopharmacology/methods , Reward , Social Behavior
SELECTION OF CITATIONS
SEARCH DETAIL
...